View:
Mini BasicThis view is available after user registration.
ShortThis view is available when you buy a license.
StandardThis view is available when you buy a license.
CompleteThis view is available when you buy a license.
Nivolumab 240 / Cabozantinib 40, Renal Cell Carcinoma
Protocol-ID: 1730 V1.1 (Mini), NIVO240/CABO40, RCCIndication(s)
- Renal Cell Carcinoma; ICD-10 C64
Links
- Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial [DOI]
- Tannir NM et al. Clin Cancer Res 2020. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma [DOI]
 | The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti. |
Valid since: 02.11.2023